Organisation paid for research Program year 2025 Source: CMS Open Payments

Centers for Advanced Urology LLC

Neither a doctor nor a teaching hospital

Research payments

$1,882,724

227 payments

Through program year 2025, Centers for Advanced Urology LLC is reported as receiving $1,882,724 in research payments, across 227 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $512,870 64
2024 Research $780,078 50
2023 Research $241,461 42
2022 Research $99,577 24
2021 Research $139,429 29
2020 Research $102,808 17
2019 Research $6,500 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $1,845,852 221 payments
  2. Ferring Pharmaceuticals AS $22,322 2 payments
  3. Exact Sciences Corporation $11,650 2 payments
  4. GlaxoSmithKline, LLC. $2,900 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $549,571 28 payments
  2. A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $510,908 63 payments
  3. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $109,544 14 payments
  4. A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc $100,889 9 payments
  5. A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases $88,588 15 payments
  6. A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer $74,869 4 payments
  7. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $74,346 13 payments
  8. A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo $51,751 11 payments
  9. A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients $47,962 2 payments
  10. MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM $42,308 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record